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1Abstract
This article explores some of the medical and ethical issues that surround the selection of 
persons to receive anti-retroviral therapy (ARV) for HIV-AIDS. It is empirically 
grounded in the experiences of the project to prevent and treat AIDS conducted by 
Médecins Sans Frontières (MSF) in Khayelitsha, a densely populated, highly 
disadvantaged, urban township on the periphery of Cape Town, South Africa. The article 
describes and analyzes the so-called “selection process” that the project’s staff uses to 
determine which patients to start on ARV therapy; the medical, social, and adherence 
criteria on which they try to base their decisions; the emotional and moral strains that this 
entails for them; and their overall reluctance to refuse anyone for treatment. It depicts the 
evolution that the process has undergone as it has moved progressively toward becoming 
a system to prepare patients for treatment and help them to adhere to the drug regimen, 
rather than to select or de-select them. The article ends with brief reflections on the 
macro-implications of the Khayelitsha project’s experiences in grappling with these 
issues for dealing with them nationally, in South Africa, the country with the world’s 
largest number of HIV-positive persons.
2Introduction: Underlying Assumptions and Questions
This paper explores some of the medical and ethical issues that surround the 
selection of persons to receive treatment for HIV/AIDS with anti-retroviral therapy 
(ARV), and the complex, often troubling process that making such decisions involves. It 
is empirically grounded in the evolving experiences of the project to prevent and treat 
HIV/AIDS that operates under the auspices of Médecins Sans Frontières (MSF) in 
Khayelitsha, a township in the Western Cape of South Africa, located 30 kilometers from 
the center of Cape Town.
Underlying the observations and reflections upon them that we report is our 
ethical assumption that access to AIDS treatment is a human right and that ideally, it 
should be guided by principles of fairness and equity.  
Fundamental to considerations of “patient selection,” in our view, is a cluster of 
interrelated medical, motivational, and ethical questions: When should patients be started 
on ARV treatment? Can and should it be ascertained in advance of initiating this therapy 
whether patients will prove to be willing and able to take the ARV medications regularly, 
in order to produce long-term viral suppression, and minimize the risk of the 
development of drug resistance?  Can patients be helped to adhere to the treatment? If so, 
in what ways?  And to what extent should the health care team be responsible for 
fostering this adherence?       
We recognize that prioritizing patients for treatment, along with treatment for 
patients, is not unique to HIV/AIDS. Rather, it is common in the practice of medicine –
especially in the delivery of care for serious, prolonged, chronic diseases, particularly in 
the face of problems of scarce, medically relevant resources, and their allocation.  But, in 
3our opinion, because HIV/AIDS is an ultimately fatal infectious disease that has reached 
global pandemic proportions, and its public health as well as its clinical management is 
affected by the behavior both of those who receive treatment and those who do not, 
setting priorities for the groups or categories of people who will have access to therapy 
takes on added significance. 
This article rests on one other set of assumptions. We feel strongly that what is 
termed in medical and public health literature “scaling up” access to ARV therapy for 
HIV/AIDS is urgent, on a country-by-country basis, and internationally, with the goal of 
progressively achieving universal access to treatment for all persons who might benefit 
from it.  However, since this goal cannot be realized instantaneously, but will necessarily 
entail an incremental process of some duration, for a period of years to come “scaling up” 
will not dispel issues of patient selection, as we shall briefly discuss in the concluding 
section of this article.
The MSF Khayelitsha Project  
Since May 2001, MSF has been providing anti-retroviral treatment for persons 
with HIV/AIDS who reside in the township of Khayelitsha. This program, which is 
carried out in the HIV/AIDS clinics that MSF has established in each of Khayelitsha’s 
three community centers, has become an integral part of the project that MSF launched in 
1999 to explore and demonstrate the medical and economic, and the social and cultural 
feasibility of preventing and treating HIV/AIDS in a so-called “resource-poor,” 
economically and socially disadvantaged setting. MSF’s decision to include ARV therapy 
in its project was made in agreement with the Western Cape Provincial Department of 
4Health; and in February 2002, it moved from its pilot status to become a fully 
institutionalized part of the overall MSF project.
i  
Khayelitsha is an enclave of some 500,000 inhabitants, most of whom live in 
corrugated-iron shacks, without running water or electricity. Unemployment is soaringly 
high; crime and violence (including robbery, domestic violence, rape, and murder) are 
rampant. The general prevalence of HIV/AIDS is also very high – 26%, measured among 
pregnant women. The tuberculosis incidence rate is one of the world’s highest for open-
space sites (1380/100,00). TB/HIV co-infection is very high as well: 63% of the persons 
with TB are infected with HIV.  
In a microcosmic, highly concentrated and accentuated way, these data reflect the 
epidemic proportions of HIV/AIDS in South Africa. Out of a national population of some 
45.5 million people, there are as many as 5,200,000 persons who are currently HIV-
positive  -- more than in any other country.  In 2004, 311,000 persons died of HIV/AIDS-
related diseases (almost 900 every day). 
The treatment component of the MSF Khayelitsha project is centered around the 
deployment of first-line, high-acting, anti-retroviral drugs (HAART),  in a three-drug 
regimen of Stavudine or AZT, Lamivudine, and Nevirapine or, in the case of persons 
with concomitant tuberculosis, Efavirenz. Mainly high quality, relatively low-cost, 
generic forms of these drugs are used. 
ii
 The aim of this triple therapy is to arrest the progression of the disease by 
keeping the viral load low enough to enable the symptoms of this ultimately fatal disease 
to be managed, so that the persons afflicted with it can meet the demands of everyday 
living for as long as possible, and their survival time will be extended. Once this 
5treatment is begun it entails the faithful, continuous taking of the medications for the rest 
of a patient’s life. The daily pill burden varies according to the regimen, but in a country 
like South Africa, where fixed dose combinations are not yet available, it involves taking 
4 to 7 pills a day. If the individual with AIDS fails to take the drug regularly, the HIV 
virus which “learns quickly,” will multiply rapidly, develop ways of escaping the 
treatment forever, and the patient will swiftly succumb to the disease. If such a person is 
not practicing “safe sex,” there is the public health danger that he/she may transmit this 
drug-resistant form of the virus to others. 
At present, 8,000 persons with HIV/AIDS are being treated in the three MSF 
clinics. 1,500 of these patients are currently receiving ARV therapy, including 100 
children. Two permanent physicians are assigned to each clinic. These physicians, along 
with two to three nurses and three counselors, make up the team in attendance at every 
clinic session. Physicians deal primarily with patients in advanced clinical stages of the 
disease, who are not yet receiving ARV medication. Because these individuals are 
desperately ill, and susceptible to severe, recurrent, opportunistic infections, it is felt that 
the expertise of a physician is needed to handle the intricate, life-threatening 
complications that their situation presents. Nurses are the cornerstone of the clinic work, 
taking responsibility for most of the continuing and follow-up care of both ARV and non-
ARV patients. However, physicians manage the serious side-effects of the ARV 
medications, and problems of resistance to the drugs that may occur. The counselors’ 
work focuses mainly on preparing patients for ARV therapy, furthering their 
understanding of the disease and its treatment, promoting their adherence to the drug 
regimen, and involving them in support groups,
6One of the Khayelitsha project’s most distinctive characteristics is that, without 
becoming politicized, it has been collaborating with the Treatment Action Campaign 
(TAC), an HIV/AIDS-dedicated, South African civic organization that developed out of 
the tradition of the antiapartheid movement. TAC has led a powerful struggle to raise 
local and national consciousness about the HIV/AIDS epidemic, advance openness about 
it, reduce the stigma associated with it, implement educational programs to lower its 
incidence, prevent its transmission, develop “treatment literacy,” and put the Government 
under pressure to enact a national HIV/AIDS prevention and treatment program that 
includes anti-retroviral therapy for all people in South Africa who need it.
The “Patient Selection” Process and Its Evolution
This is the framework within which the Khayelitsha project has grappled since its 
inception with what it considers to be one of the most difficult and disturbing problems 
that it faces – namely, how to decide which patients to start on ARV therapy, and when to 
do so, using criteria for these decisions that are both medically sound and ethically just. 
The fact that MSF is a movement and an organization that operates within a culture of 
inquiry and debate about its medical humanitarian and human rights witnessing action, 
has contributed to the staff’s continuous concern and discussion about what they refer to 
as this problem of “patient selection.” However, as our descriptive analysis of the 
decision-making process in which they actually engage will reveal, there is a fundamental 
sense in which the term “selection” is a misnomer.
In the earliest days of the Khayelitsha project, when it was totally supported by 
MSF and had only enough funding to treat 180 patients with ARV therapy, it used what 
its personnel experienced as a dismaying process of drastic selection based on a “priority 
7scoring system.” Priority scores were rapidly abandoned at the end of 2003 when MSF 
committed sufficient funds to the Khayelitsha undertaking to make treatment for 400 
persons possible.
iii It was at this juncture that the project established a so-called 
“selection” committee, composed of clinical staff members.  The committee was 
centrally run, met once a month, and strove to attain impartiality in the decisions it made, 
through abiding by norms of strict anonymity and transparence, and the participation of a 
large community representation in its proceedings. Their decisions concerned starting 
patients on anti-retroviral therapy, based on an ensemble of medical, social, and what 
were called “adherence” criteria. The latter consisted of criteria that were considered to 
be indicators that patients provided with ARV therapy would take the medication 
faithfully and regularly.  
On November 19, 2003, the Department of Health of the South African 
government approved a long-awaited Operational Plan for Comprehensive Treatment and 
Care for HIV and AIDS that set into motion a political process to progressively make free 
anti-retroviral medication available to all citizens of the country with HIV/AIDS.
iv This 
national “roll-out” development unlocked international funding mechanisms, with the 
result that since July 1, 2004, 80% of Khayelitsha’s financial support comes from the 
Global Fund to Fight AIDS, Tuberculosis and Malaria (which it receives via the Western 
Cape Provincial Government), and 20% from MSF. As a consequence, money is no 
longer a bottleneck for the Khayelitsha project, which now has sufficient financial 
resources to enroll as many persons with HIV/AIDS in the township for ARV treatment 
as they deem they can handle. Financially, the project is moving closer to assuring 
8universal coverage in Khayelitsha; and in the course of 2005, it hopes to be able to meet 
100% of the pediatric and 50% of the adult needs for treatment.
At present, it is shortage of staff rather than restrictions in funding that limits the 
number of patients the project feels it can enroll for treatment.  Although public health 
salaries in South Africa are ample enough to have attracted medical and nursing 
personnel from neighboring countries, South African physicians and nurses have been 
emigrating in sizable numbers to societies such as the United Kingdom, Canada, 
Australia, and the United States, where they can expect to earn higher incomes. The HIV 
virus is also contributing to the dearth of available health professionals, many of whom 
have been stricken with AIDS.
v
This deterrent notwithstanding, the significant increase in funding has enabled 
Khayelitsha to considerably expand its patient enrollment (from an average of 32 new 
patients per month in 2003, to 97.5 a month in 2004); and it has led them to alter the 
organization of its selection committee and its procedure. Instead of one central selection 
committee for the entire Khayelitsha site that formerly existed, what is still called a 
selection committee has been established in each of the three HIV clinics. These 
committees meet fortnightly; are mainly composed of, and managed by clinical staff; and 
also include one patient in its membership who is defined as an “external witness.” 
At the meetings of the selection committees, a clinical nurse presents patient-
candidates who are regarded by the staff as potentially qualified to be put on ARV 
therapy, and most urgently in need of receiving it. A set of medical, social, and adherence 
criteria are used to arrive at this evaluation. Medically, the patient must have undergone 
two tests that confirm his/her HIV serostatus, and should be in what the World Health 
9Organization designates as stage 4 of the disease, or in stage 1, 2, or 3, if the patient’s 
CD4 count is <200 cells/mm
3. Tuberculosis is considered a medical contraindication for 
initiating ART unless the patient’s CD4 count is < 200 cells/mm
3. The social criteria 
include a record of regular clinic attendance by the patient (at least four scheduled visits 
to the HIV clinic); the patient’s commitment to staying in Khayelitsha for at least six 
months, to long-term anti-retroviral therapy, and to safe sex practices (“condomizing,” or 
abstaining from sexual relations); the willingness of the patient to disclose his/her HIV 
status to a person in their confidence (older than 18 years of age), who also agrees to act 
as the patient’s treatment assistant; and readiness to attend a support group for persons on 
ARV therapy for at least once a month during the first year of treatment. Alcohol or other 
substance abuse, and untreated active depression are regarded as social contraindications 
for initiating ARV therapy. The main adherence criteria consist of the patient’s 
presentation on time to the last four medical consultations (“on time” is liberally defined 
as on the day of the scheduled clinic visit); attendance at a minimum of three intensive 
counseling sessions; and agreement to a preliminary home visit by a counselor or nurse to 
discuss the treatment with the patient and the treatment assistant, if there is uncertainty 
concerning his/her ability to meet any of the criteria.
vi In principle, fulfillment of all 
medical, social, and adherence criteria is required for beginning ARV therapy.
The primary data reported by the clinical nurse at selection committee meetings 
are medically relevant facts concerning the patients under consideration: their date of 
birth, gender, the date when they were first seen in the clinic and diagnosed as HIV-
positive, the number of visits they have made to the clinic, their CD4 count, the stage of 
the disease they are in, what opportunistic infections they have had, and whether they 
10have a concomitant diagnosis of tuberculosis. The physician (or physicians) participating 
in the meetings focus on the medical (biological and clinical) criteria, and on what is 
euphemistically called patient “fitness” to begin ARV therapy. The latter chiefly refers to 
the program’s inclination to exclude patients with active tuberculosis, because of the high 
probability that after the initiation of ARV treatment such patients will develop an 
immune reconstitution that will cause their clinical status to worsen. Counselors have the 
final word in the decisions taken regarding when the treatment should begin; and they are 
responsible and accountable for long-term patient adherence.
On the average, some 30 to 40 patient-candidates are reviewed by each clinic, 
each month.
Reluctance to Refuse Anyone for ARV Treatment
Despite the elaborate, well thought-out set of criteria that presumably guide the 
selection committees’ appraisal of patients’ suitability to receive ARV therapy, the most 
striking result of their deliberations is that in almost every instance, the decision is taken 
to “accept” the patient for treatment. When it is reported that a candidate slated to begin 
the therapy has not met certain of the social and adherence criteria – such as readiness to 
use condoms, the punctual keeping of clinic appointments, regular participation in a 
support group, or disclosure of HIV/AIDS status – the tendency is still to admit the 
person into the ARV program. The staff views meeting these criteria and abiding by 
them, dynamically, as conditions that patients can be helped to fulfill  -- both before and 
after the initiation of treatment -- with the help of counselors, and of fellow-patients. 
“Preparing” patients for treatment, as this process is called, has become so predominant 
11that, with humor-tinged seriousness, some staff members have suggested that the 
“selection” committees ought to be renamed  “patient readiness” committees.
“We never definitely give a ‘no’ to any patient for ARV,” one of the MSF 
physicians declared. “This is felt to be unethical. We just say, ‘Not ready.’”  The closest 
that they come to turning a patient down, he contended, was illustrated by a case in which 
the period of “temporary refusal of ARV treatment” was so prolonged that “when we 
finally gave the green light [to start it], it was too late”:  
X was a 26 year-old woman, with HIV/AIDS, who was living alone with her 16 
year-old daughter. She had also developed pulmonary tuberculosis, and was not 
able to adhere to the course of treatment for it. The decision was made to send her 
to the local hospice run by the Order of Mother Teresa’s Sisters (the Missionaries 
of Charity), where she could receive supervised TB therapy. She improved 
dramatically under their care. She insisted on being discharged from the hospice 
before the Khayelitsha team could start her on ARV medications, and then 
disappeared from their view. Three months later, she returned to Khayelitsha, and 
was seen in one of the HIV/AIDS clinics, where she was found to be in an 
emaciated state, with a very large ulcerated herpes zoster, and urgently in need of 
ARV treatment. Because of her previous record of irregularity in keeping 
appointments, and her non-adherence to TB therapy, it was decided that her ARV 
treatment would have to be carried out under supervision, and that she should be 
readmitted to the hospice for this purpose. It took her a long while to accept these 
conditions, and when she finally did, she was in the terminal stage of HIV/AIDS. 
12She was immediately started on ARV therapy, but she died in the hospice a few 
weeks later. 
The Khayelitsha team finds it difficult to accept the possibility that certain
patients may  never be able to reach or maintain the “preparedness” level  to receive ARV 
treatment required by the social and adherence criteria, despite all the coaching and 
support they receive, and that under these circumstances, ARV therapy should not  be 
started in the first place or,  if  a patient is already receiving the therapy, the decision 
should be made to withdraw it:
L., a 32 year-old, male patient, was among the first to be enrolled in the 
Khayelitsha ARV program. Although the selection committee was aware of the 
fact that he was violent with his girlfriend, and that he abused alcohol, they 
believed that he would be able to turn his life around and stabilize it. Their 
confidence in his capacity to do so was based on their admiration for his dedicated 
involvement in the Treatment Action Campaign (TAC). L. had organized a TAC 
branch close to his home, and worked commitedly to promote access to treatment 
for HIV/AIDS. However, he was never able to find regular paid employment. 
Shortly after starting ARV treatment, L. ceased to adhere to the mandatory 
drug regimen. Subsequently, the clinic staff learned that this was due to the fact 
that he had been hospitalized for a broken arm caused by a gunshot wound. 
Therapy was rapidly resumed, and he improved significantly; but after six months 
of therapy, his non-adherence to treatment became manifest. His CD4 count was 
13barely improving, and his viral load remained detectable at three- and six-month 
routine checkups. Shortly after nine months on ARV medications, his clinical 
status worsened, and he developed pulmonary tuberculosis. He was urged by the 
staff to attend intensive counseling sessions, which he did. He improved once 
more for a short while, but “defaulted” again in the taking of his medications, and 
vanished from sight. When he reappeared, his clinical status had deteriorated still 
further. At this point, the Khayelitsha team painfully decided to withdraw ARV 
treatment, not only because the clinical signs indicated that it was not benefiting 
him any more, but also because they hoped that this would produce a “reality 
shock” that would forcefully remind him about the importance of “regularity” and 
“adherence.” 
Their strategy did not work. L. died from disseminated tuberculosis, 18 
months after he had received his first dose of anti-retroviral drugs. 
One could say that virtually until the day that L. died, the staff did not
relinquish their intention of finding a way to maintain him on ARV therapy. In their eyes, 
his was a “tragic history.” His way of life, and the “competing priorities” in it, they felt, 
grew out of his enormous personal frustration over his unemployment, and his 
consequent inability to “put bread on the table,” and fulfill other traditional obligations of 
a Xhosa-African man (a predicament that pervades the lives of the male inhabitants of 
Khayelitsha.) Although he tried to cope with his frustration through his HIV/AIDS-
focused political activism, he never succeeded in sufficiently “overcoming his demons,” 
as one physician put it, “to achieve regularity in treatment.” There is a sense in which the 
14staff’s understanding of L.’s social, economic, and cultural situation, and his reactions to 
it made it harder for all of them to take the decision that they did. In the end, however, it 
was the doctor in charge of the case who was the most emotionally and ethically 
disturbed by the outcome. Although he regarded the withdrawal of ARV therapy as 
clinically justified, he felt a sense of responsibility and of failure over the fact that this 
decision  “did not offer any future to a charismatic patient.” The chief counselor who was 
involved in the case found some consolation, as well as justification, in the fact that 
according to the criteria of patient adherence, which it was her professional obligation to 
monitor, the decision to stop treatment was the “right one”.
Reluctance to Accept Patients’ Refusal to Begin Or Continue ARV Treatment
The medical staff is also averse to passively agreeing to the disinclination of some 
patients to start, or continue ARV therapy:
A., a terminally ill, 34 year-old man, with a CD4 count of 9, in Stage 4 of 
HIV/AIDS, was described in a selection committee meeting as having displayed 
“repeated adherence problems” in the past. He had failed to show up for clinic 
appointments, and at one point had “disappeared” from Khayelitsha, when he 
returned to the Eastern Cape, his region of origin, for a prolonged period of time. 
It was reported in the meeting that A. had vocally objected to the fact that family 
members – particularly his aunt, who was his devoted caretaker – were “forcing” 
him to seek treatment. The committee engaged in more discussion about this 
patient than usual, especially because A.’s aunt strongly advocated that he receive 
treatment, but his HIV/AIDS had progressed so far that he was no longer 
“responding,” and able to give his own informed consent for it. Although the 
15physician presenting A.’s case stated that “even if we start him now [on therapy], 
he is likely to die in a month,” the committee decided to immediately begin 
treating him with ARV drugs, and to monitor his case on a weekly basis.
S., a 31 year-old taxi driver, was sent to the Khayelitsha HIV/AIDS clinics by the 
GF Jooste Hospital, the project’s referral hospital. He had been diagnosed with 
criptococcal meningitis, and was in Stage 4 of HIV/AIDS. His wife and five year-
old son were also HIV positive. Because of the clinical stage of his disease, he 
was rapidly selected as a candidate for ARV medications. However, he refused to 
start treatment for several months, insisting that he wanted his wife to become 
pregnant before he began the therapy. Having sexual intercourse with his wife 
without using a condom contravened the safe sex policy to which patients being 
cared for in the program were expected to adhere.
S.’s wife, who was well informed about HIV issues, was started on 
ARV’s. Two months later, she became pregnant. Once this occurred, S. stated that 
he was now ready for ARV therapy, and his treatment was begun. His wife then 
underwent an abortion, claiming that ARV drugs had toxic effects on a 
pregnancy.  Subsequently, both she and her husband stopped taking the ARV 
medications. 
Their current whereabouts are unknown to the Khayelitsha staff – but 
were they to appear again, it is not inconceivable that the decision would be made 
to resume their ARV treatment.
16Sources and Persistence of “Patient Selection” and 
“De-selection” Issues 
The unwillingness of the selection committees to outrightly refuse anyone for 
ARV treatment, their conviction that to say  “no” unconditionally and definitively is 
unethical, the suasion and support that they marshal to get and keep patients on the 
regimen, and their tendency to find extenuating reasons to explain and override 
indications that a patient has not met the selection criteria, continued to fulfill them, or 
wishes to stop the treatment, stem from a number of sources. Above all, there is their 
shared belief in the restorative powers of ARV therapy, and their commitment to the 
mission of giving every patient with HIV/AIDS  “a chance,” by making the treatment 
available to all who might benefit from it. Furthermore, they are concerned about 
insuring that they do not end up acting as a judgmental “tribunal,” making life-or-death 
decisions in the process of trying to ascertain which patients will, and which will not do 
well on ARV therapy. This is particularly apparent when they are confronted with 
patients in a very advanced, rapidly evolving stage of HIV/AIDS, who have a high risk of 
imminent death. In such instances, when the medical staff, along with the selection 
committees are brought face-to-face with the fearsome question of how to decide, ”Who 
shall live when not all can live?”
vii, they are inclined to allow these persons to “jump the 
queue” of what are usually some 500 patients with CD4 counts of less than 200/ml who 
are waiting to begin ARV therapy. They do so with the uncomfortable knowledge that 
such  “fast-tracked” patients will not only delay the treatment of other patient-candidates 
who may have been waiting longer, but may also contribute to the further deterioration of 
their immune function because of the extended waiting time.
17The difficulty that the members of the Khayelitsha selection committees have in 
cleaving to the formal criteria that they have devised for determining if and when a 
patient is ready to start ARV therapy, and in denying any patient the opportunity to 
receive it, calls to mind for one of us (RCF) comparable problems that the Admissions 
and Policy Committee of the Artificial Kidney Center in Seattle, Washington, USA 
experienced during the 1960s. This committee was confronted with the task of screening 
and selecting patients with end-stage renal disease for chronic intermittent hemodialysis, 
in an era when the limited number of kidney machines and financial resources available 
for this purpose made it impossible to accept every patient who was potentially medically 
eligible to receive the treatment. The committee drew up a number of social and 
psychological, as well as medical criteria for selecting which patients were given access 
to this life-prolonging therapeutic procedure. Nevertheless, like their Khayelitsha 
counterparts, committee members were disinclined to strictly apply them to their 
decision-making. It was striking to observe how few of the selection/de-selection criteria 
that they were supposedly utilizing ended up disqualifying a candidate for the procedure. 
In effect, in common with the Khayelitsha committees, the Seattle committee was 
oriented to selecting, rather than refusing the patients whose cases came before them.
viii 
It might be supposed that the issues surrounding patient selection for ARV 
treatment, and the clinical and moral dilemmas and emotional strains that they pose for 
health care workers would be dispelled by changes in economic, political, and social 
conditions that made these drugs available to all who need them. However, some of the 
consequences of the financial “democratization” of dialysis in the United States are 
instructive in this regard because they suggest that this may not be the case, and that more 
18than the problem of scarce funds and therapies and their allocation are involved.
ix In 
1972, the U.S. Congress passed a law that, under Social Security, extended Medicare 
coverage insurance for the treatment of end-stage renal disease by dialysis and/or kidney 
transplantation to almost the entire American population.
x But the unease that physicians 
had previously felt about “playing God” in their role as gatekeepers of dialysis was not 
done away with by universal financial accessibility to this treatment; and in certain 
respects, it was replaced by new sources of disquietude. The major issue that physicians 
now faced was that with payment guaranteed, using biological and clinical, as well as 
psychological and social criteria of patient selection became so questionable that they felt 
there was now virtually no way to turn anyone with end-stage renal disease down for 
dialysis that would be considered either medically or morally defensible. What some 
nephrologists referred to as the “de-selection” of patients for this mode of treatment 
because it would not benefit them, would subject them to a dubious quality of life, or 
even (as Belding Scribner, the inventor of chronic intermittent dialysis put it) entail  “a 
fate worse than death” for them, became acutely problematic.
“Scaling Up” and Selection 
The so-called “universal roll-out” of ARV therapy for all who need it has only 
begun in South Africa, and the country is still far from dealing with, or even anticipating 
what patient selection and de-selection issues achieving that goal might entail. But the 
process of “scaling up” ARV treatment that has been launched, already makes it apparent 
that the problems of selecting patients for ARV therapy with which the MSF project has 
been struggling in the microcosm of Khayelitsha will not only persist for some time to 
come, but may even be amplified in certain ways. 
19Expanding AIDS treatment on a national scale is an intricate and ramifying public 
health challenge. A distributive ethic, oriented to the greatest number of persons in all 
regions, communities, economic, social, and cultural groups in the country, rather than to 
an individual ethic that gives precedence to the well-being of each patient in a one-on-one 
relationship to health care professionals, will have to prevail. It is likely to be 
accompanied by areas of tension between them. The South African government’s 
Operational Plan for Comprehensive Treatment and Care for HIV and AIDS will need to 
be phased in incrementally, bringing in its wake questions about the order in which 
treatment centers will be established in the different districts of the country, and the 
priority and provisions assigned to them.  The foremost hindrance to the full 
implementation of this plan is the dearth of physicians and nurses to treat and care for all 
the persons with HIV/AIDS in the population, rather than insufficient funds or supplies of 
affordable ARV drugs.
xi What is more, expanding ARV treatment on a society-wide scale 
will probably require major changes in the entire South African health care system, 
whose current status is described by professor of medicine Solomon R. Benatar in the 
following way: 
xii
Considerable legislation has been passed with a view to achieving greater equity 
in access to healthcare with a district-based primary health care system. To 
achieve this, national public health resource allocation is focused on redistribution 
away from tertiary care towards primary health and community-based care. 
However, excessively rapid transformation toward these goals has resulted in 
dysfunctional primary services and attrition of tertiary services in the public 
20sector with greater losses than gains in healthcare in the short term and adverse 
implications for the future. 
Within this already burdened system of health care delivery, major issues of how
to allocate its personnel, facilities, and energies between the treatment and care of 
persons with HIV/AIDS, and all the other health and medical problems of the country’s 
citizenry will arise, and require developmental solutions.
***
It is the hope of the MSF Khayelitsha program that what they have learned on a 
local scale from their first-hand experience in dealing with medical and ethical issues of 
what they call “patient selection” can make a constructive and edifying contribution to 
this at once urgent and formidable societal process.  
        
     
      
               
      
.
21i The first MSF mission to incorporate anti-retroviral therapy into its HIV-AIDS-oriented medical program was undertaken 
in Bangkok. The project in Khayelitsha was the second one, and MSF’s first in Africa. At present, 55 such MSF programs 
exist in 27 countries, which treat a total of more than 23,000 patients.
Initially, the Khayeltisha program was mainly supported by private funds from different MSF sections, Belgian and 
Danish Cooperation funds, and the Letten Foundation in Norway, and with funds from the Provincial Government of the 
Western Cape.
Building on their Khayelitsha experience in a highly disadvantaged urban township, in 20003, MSF South Africa, 
with the help of financial and moral support from the Nelson Mandela Foundation, inaugurated a program to prevent and 
treat HIV/AIDS in a remote, impoverished rural milieu in the Eastern Cape of South Africa (Lusikisiki). Lusikisiki suffers 
from the kind of poor health infrastructure and scarcity of health staff that is common to such distant rural areas in Africa, 
and that makes the effective implementation of HIV/AIDS services – especially in the face of the adult prevalence rate 
between 30% and 35% with which it is confronted – a daunting challenge. Nevertheless, the program managed to start 500 
patients on ARV therapy during its first year of existence.   
ii Originally, these drugs were mainly imported from a state-controlled Brazilian company, but at present, they are chiefly 
supplied by Indian companies; and most recently, the first-line, three drug regimen has been offered to public services for 
$15 U.S. dollars per month by Aspen Pharmacare of South Africa. Aspen, based in Johannesburg, is the largest drug 
company in Africa. It has the permission of GlaxcoSmith Kline and of Boehringer-Inglelheim to make generic versions for 
the South African market of the AIDS drugs on which these pharmaceutical firms have patents.  
iii In 2004, MSF increased its funding once more, making it possible to cover the costs of offering ARV treatment to 600 
persons.
iv The implementation of this planned program has been slow. No more than 65,000 persons out of the more than  500,000 
individuals in the country who need anti-retroviral therapy immediately to stay alive are currently receiving it.
v The program that MSF created in Lusikisiki, in  a  very poor and isolated area of the Eastern Cape,  is having much more 
difficulty in recruiting  physicians and nurses than Khayelitsha.
vi In an earlier phase of the Khayelitsha project, when funding and access to ARV drugs were scarcer, a home visit to every 
prospective recipient of treatment was required. At present, this only takes place if counselors feel that they do not have 
enough information about a patient’s family or residence. 
vii Childress JF. Who shall live when not all can live? Soundings 1970; 43 (winter): 339-355.
viii Fox RC and Swazey JP The Courage to Fail:  A Social View of Organ Transplants and Dialysis. Chicago: University of 
Chicago Press, 1974 and 1978 (second, revised edition), and New Brunswick (USA) and London (UK):  Transaction Books, 
2002 (republished with a new Introduction). See especially, Chapter 8, “Patient Selection and the Right to Die: Problems 
Facing Seattle’s Kidney Center,” pp. 226-265.
ix For a detailed account of some of the unanticipated as well as anticipated consequences of  the “democratization of 
dialysis,” see Chapter 11 in Fox and  Swazey, The Courage to Fail. University of Chicago Press, 1978 (second, revised 
edition), and Transaction Books, 2002, pp. 345-375.
x Public Law 92-603 was passed on October 30, 1972.
xi This problem exists throughout the continent of Africa. In a report released on November 26, 2004, the Joint Learning 
Institute, a research group of some 100 scholars and experts, financed by the Rockefeller Foundation and the Bill and 
Melinda Gates Foundation among others, stated that Africa needs a million more health workers to deal with the HIV/AIDS 
pandemic. In this connection, it exhorts rich countries to stem the “fatal flows” of nurses and doctors from poor African 
countries to Europe and North America.  (See Dugger CW. Africa needs a million more health care workers, report says. 
New York Times  2004, 26 November: A27).
xii Benatar S. The lost potential of our health system. Cape Times 2005, 14 January.